A5101834295- Renal Diseases and Glomerulopathies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Vasculitis and related conditions
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Systemic Lupus Erythematosus Research
- Chronic Kidney Disease and Diabetes
- Ovarian cancer diagnosis and treatment
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Economic and Financial Impacts of Cancer
- Renal Transplantation Outcomes and Treatments
- Breast Cancer Treatment Studies
- Chronic Lymphocytic Leukemia Research
- Renal and Vascular Pathologies
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Pancreatic and Hepatic Oncology Research
China National Pharmaceutical Group Corporation (China)
2025
Nanjing University
2015-2024
Nanjing General Hospital of Nanjing Military Command
2015-2024
Nanjing Medical University
2018-2024
Chongqing Medical University
2013-2024
Suizhou Central Hospital
2024
First Hospital of Shijiazhuang
2024
First Affiliated Hospital of Nanchang University
2023
Nanchang University
2023
National Clinical Research
2018-2023
BackgroundThe Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy (PRIME) demonstrated that panitumumab–FOLFOX4 significantly improved progression-free survival (PFS) versus FOLFOX4 as first-line treatment of wild-type (WT) KRAS metastatic (mCRC), the primary end point study.Patients and methodsPatients were randomized 1:1 panitumumab 6.0 mg/kg every 2 weeks + (arm 1) or 2). This prespecified final descriptive analysis efficacy...
Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is approved in United States and Europe for treatment of refractory metastatic colorectal cancer (mCRC). Skin toxicities are most common adverse events with EGFR inhibitors. This first study designed to examine differences between pre-emptive reactive skin specific patients mCRC any inhibitor.Patients receiving panitumumab-containing therapy were randomly assigned 1:1 or (after toxicity...
<h3>Importance</h3> Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed. <h3>Objective</h3> To determine whether neratinib, an irreversible pan-ERBB tyrosine kinase inhibitor, plus paclitaxel improves progression-free survival compared with the first-line treatment of recurrent and/or metastatic ERBB2-positive breast cancer. <h3>Design, Setting, Participants</h3> In randomized, controlled, open-label NEfERT-T trial conducted...
BackgroundThe ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC).Patients and MethodsExteNET was a multicenter, randomized, double-blind, phase III of 2840 HER2+ eBC after neoadjuvant/adjuvant trastuzumab-based therapy. Patients were stratified by HR status...
The high overall mortality from ovarian cancer (> 60%) relates, in part, to delays diagnosis. When is detected stage I (International Federation of Gynecology and Obstetrics staging), up 90% patients can be cured. Transvaginal sonography detect early-stage disease with great sensitivity, but it expensive lacks specificity. Although serum marker assays could provide a less more convenient initial screening test, the sensitivity varies. Measurement CA 125 conjunction ultrasound as second-line...
Background: Strong associations between provider (i.e., hospital or surgeon) procedure volumes and patient outcomes have been demonstrated for many types of cancer operation. We performed a population-based cohort study to examine these ovarian resections. Methods: used the Surveillance, Epidemiology, End Results (SEER)–Medicare linked database identify 2952 patients aged 65 years older who had surgery primary diagnosed from 1992 through 1999. Hospital- surgeon-specific were ascertained...
To evaluate the changing spectrum of kidney diseases over time in China using renal biopsy-proven cases.All patients age 14 years who were diagnosed with a disease by biopsy Renal Biopsy Registry National Clinical Research Center Kidney Diseases Jinling Hospital, Nanjing, from 2003 to 2014 included.In total, 40,759 cases analyzed. The mean was 36.59 ± 14.12 years. 52.0$ male. Primary glomerulonephritis (PGN), secondary glomerulonephritis, tubulointerstitial disease, and hereditary accounted...
Abstract HER2 mutations define a subset of metastatic breast cancers with unique mechanism oncogenic addiction to signaling. We explored activity the irreversible pan-HER kinase inhibitor neratinib, alone or fulvestrant, in 81 patients HER2-mutant cancer. Overall response rate was similar without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration appeared longer ER+ receiving combination therapy, although study not designed for direct comparison....
Serum phospholipase A2 receptor antibodies (SAbs) and glomerular antigen (GAg) deposits have been observed in idiopathic membranous nephropathy (IMN). However, the clinical application of these two biomarkers, particularly GAg deposition, needs to be further evaluated. We measured SAb concentration by ELISA deposition immunofluorescence 572 patients with biopsy-proven IMN. Overall, 68.5% (392 572) had detectable (SAb+), 98.7% who were SAb+ (387 392) 70.6% SAb- (127 180) (GAg+). Compared...
Somatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active multiple HER2-mutant cancers. SUMMIT a phase II basket trial investigating the efficacy safety neratinib solid tumors.Patients HER2-mutant, persistent, metastatic/recurrent cancer disease progression after platinum-based treatment for advanced/recurrent received oral 240 mg/day mandatory loperamide...
The elderly population is prone to osteoporosis, owing the deterioration of skin, liver, and kidney functions. Vitamin D (VD) supplementation has a limited effect, VD deficiency mostly treated with medication. Several studies have shown that gut microbiota alters intestinal metabolism probiotic supplements can influence circulating levels. Therefore, in present study, we screened strain Bifidobacterium longum FSHHK13M1 increase level metabolites fermented supernatant species vitro by...
Fragmentation across sites of care may impede efficient healthcare delivery.The objectives this study were to evaluate fragmentation hospital for chronically ill New York City (NYC) residents and its association with enrollment in the State (NYS) Medicaid program.We conducted a cross-sectional using NYS Department Health's Statewide Planning Research Cooperative System discharge database. We identified 53,031 NYC admitted 3 or more times acute hospitals between 2000 2002 same principal...
Panitumumab in combination with chemotherapy was evaluated two pivotal clinical trials first- and second-line treatment of metastatic colorectal cancer (mCRC), respectively. This analysis compared the health-related quality life (HRQoL) patients or without panitumumab trials. Patients mCRC were randomised to FOLFOX (first-line trial) FOLFIRI (second-line trial)±panitumumab. The EuroQoL 5-Dimensions Health State Index (EQ-5D HSI) Visual Analogue Scale VAS) assessed at baseline monthly...
BackgroundStudies on biopsy-proven renal disease in the elderly (age ≥65 years) are extremely limited China. The aim of this study was to examine spectrum diseases and their clinical presentations patients undergoing biopsy.
Soluble urokinase plasminogen activator receptor (suPAR) was initially proposed as a pathogenic and predictive biomarker of primary FSGS, but the findings were controversial. This study aimed to clarify clinical implications suPAR.The enrolled 109 patients with biopsy-proven FSGS who administered prednisone between January 2011 May 2013 followed up for 6-24 months (median duration follow-up, 12 months). Ninety-six healthy volunteers, 20 minimal-change disease (MCD), 22 membranous nephropathy...
This study aimed to investigate renal outcomes and their predictors in biopsy-proven hypertensive nephrosclerosis (HN) patients compare clinico-pathological characteristics prognoses between benign (BN) malignant (MN) patients. Data for HN were retrospectively analyzed. Renal survival rates relationships assessed. A total of 194 enrolled; the mean age at biopsy was 43.8 years, male gender predominated (82.5 %). The median duration hypertension 5.0 systolic diastolic blood pressures 195 ± 37...
320 Background: Genomic profiling studies have reported somatic HER2 mutations in ~2–5% of biliary tract cancers (BTC). Clinical data from the SUMMIT study demonstrate that neratinib, a pan-HER irreversible tyrosine kinase inhibitor, has encouraging clinical activity multiple types HER2-mutant solid tumor malignancies. Methods: is multi-histology, open-label, phase II ‘basket’ neratinib patients with (ClinicalTrials.gov NCT01953926). Patients activating different histologies, including BTC,...
Although capsaicin has long been used as food additive and medication worldwide, its actions on gastrointestinal tract most delivery pathway have not well addressed.In the present study, we aimed to study GI of mesenteric arterioles in normal colitis mice elucidate underlying mechanisms.Vasorelaxation human submucosal from wide-type (WT) mice, TRPV1-/- TRPV4-/- (KO) were measured. The expression function TRPV channels endothelial cells examined by q-PCR, immunostaining, Ca2+ imaging membrane...